Nanoformulations in Acne Therapy: Translational Opportunities and Barriers for Next-Generation Topical Treatments

Acne vulgaris is highly prevalent and burdensome, yet conventional topical therapies are limited by poor stratum corneum penetration, follicular obstruction, low drug deposition at pilosebaceous targets, drug instability, local irritation/side effects, and variable patient adherence. This review synthesizes recent nanoformulation advances in the context of acne pathophysiology and the specific delivery barriers it creates. Lipid-based carriers (solid lipid nanocarriers (SLNs), nanostructured lipid carriers (NLCs), nanoemulsions (NEs)) and vesicular systems (liposomes, niosomes, transfersomes) can protect labile actives, enhance appendageal/follicular access, and modulate release to limit irritation, while polymeric platforms (micelles, microsponges, nanoparticles) further improve residence time and controlled delivery. Early clinical studies suggest improved lesion reduction and tolerability versus conventional vehicles; however, broader translation remains constrained by manufacturing reproducibility, scale-up, regulatory clarity, long-term safety evaluation, and cost-effectiveness. As forward-looking avenues, multifunctional co-delivery (e.g., retinoid with antibiotic/anti-inflammatory), energy-responsive adjuncts (photothermal or precision cryo as non-drug complements), and green, biodegradable materials are being explored to better tackle biological challenges such as hyperkeratinisation-related obstruction, biofilms, and irritation, while aligning with sustainability goals. Overall, nanoformulations offer a credible path to more effective, patient-centered topical acne therapy; realizing this potential will require rigorous, adequately powered clinical trials, standardized dermatopharmacokinetic endpoints, and quality-by-design scale-up to bridge laboratory promise to practice.